GleamWall
中文EN

GOVX GeoVax Labs, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 832489 · Fiscal year ends 12/31

Financial factors as of 2026-03-31 (2026Q1), TTM = sum of the last four quarters

Growth

TTM revenue YoY-84.8%
TTM net income YoY12.8%
TTM EPS YoY—
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-2,523.4%
Net margin-2,507.3%
FCF margin-2,236.0%
EBITDA margin-2,515.9%

Returns

ROE-509.3%
ROA-309.3%
ROIC (approx.)—
Asset turnover0.12x

Leverage & solvency

Liabilities / assets83.4%
Debt / equity0.00x
Current ratio1.06x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.89x
Accruals ratio-33.6%
Payout ratio—
Capex / revenue1.3%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$0$0$0$0$0$852,282$1.64M$864,415
R&D expense$2.82M$3.11M$3.90M$2.99M$5.04M$4.73M$5.35M$7.61M
SG&A expense$1.35M$1.33M$1.37M$1.45M$1.33M$1.54M$1.69M$1.60M
Operating income-$4.17M-$4.44M-$5.27M-$4.44M-$6.37M-$5.42M-$5.41M-$8.34M
Interest expense———$0$0$0—$0
Income tax$0$0$0—$0$0$0—
Net income-$4.16M-$4.43M-$5.26M-$4.42M-$6.32M-$5.37M-$5.36M-$8.26M
EBITDA-$4.17M-$4.43M-$5.26M-$4.42M-$6.36M-$5.40M-$5.39M-$8.32M
EPS (basic)-10.56-0.97-2.62—-150.68-8.74-11.20—
EPS (diluted)————————
Balance sheet
Cash & equivalents$2.15M$3.14M$1.27M$3.09M$5.01M$3.09M$7.44M$5.51M
Receivables———$0$0$532,771$1.50M$659,409
Current assets$3.11M$4.18M$2.43M$5.31M$6.52M$5.14M$10.61M$7.93M
PP&E, net$10,551$84,678$96,754$108,830$127,060$143,862$149,947$149,974
Total assets$3.42M$4.64M$2.98M$6.34M$6.73M$5.35M$10.83M$8.16M
Current liabilities$2.14M$2.71M$2.29M$1.94M$1.82M$2.53M$2.94M$3.11M
Total liabilities$2.28M$2.88M$2.49M$2.52M$1.82M$2.53M$2.94M$3.11M
Shareholders' equity$1.15M$1.76M$493,770$3.83M$4.91M$2.82M$7.90M$5.05M
Shares outstanding420,9537.37M2.82M72,17329.71M15.92M13.84M421,475
Cash flow statement
Operating cash flow-$4.34M-$3.66M-$3.54M-$4.96M-$6.21M-$4.33M-$5.97M-$7.75M
Capital expenditure$0$0$0$0$0$10,718$16,894$0
Free cash flow-$4.34M-$3.66M-$3.54M-$4.96M-$6.21M-$4.35M-$5.98M-$7.75M
Investing cash flow$7,000$0$0$0$0-$10,718-$16,894$0
Financing cash flow$3.34M$5.53M$1.72M$3.04M$8.13M$209$7.91M$4.67M
Depreciation & amortization$8,542$12,076$12,076$18,230$16,802$16,803$16,921$21,641
Stock-based compensation$221,639$163,746$219,317$252,124$277,546$292,740$292,744$139,345

Free plan shows the latest 8 periods; Pro shows all 66 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.